Late sodium current block for drug‐induced long QT syndrome: Results from a prospective clinical trial

Drug‐induced long QT syndrome has resulted in many drugs being withdrawn from the market. At the same time, the current regulatory paradigm for screening new drugs causing long QT syndrome is preventing drugs from reaching the market, sometimes inappropriately. In this study, we report the results of a first‐of‐a‐kind clinical trial studying late sodium (mexiletine and lidocaine) and calcium (diltiazem) current blocking drugs to counteract the effects of hERG potassium channel blocking drugs (dofetilide and moxifloxacin). We demonstrate that both mexiletine and lidocaine substantially reduce heart‐rate corrected QT (QTc) prolongation from dofetilide by 20 ms. Furthermore, all QTc shortening occurs in the heart‐rate corrected J‐Tpeak (J‐Tpeakc) interval, the biomarker we identified as a sign of late sodium current block. This clinical trial demonstrates that late sodium blocking drugs can substantially reduce QTc prolongation from hERG potassium channel block and assessment of J‐Tpeakc may add value beyond only assessing QTc.

[1]  D. Roden,et al.  Mexiletine in the Treatment of Resistant Ventricular Arrhythmias: Enhancement of Efficacy and Reduction of Dose‐related Side Effects by Combination with Quinidine , 1983, Circulation.

[2]  R. Millard,et al.  Reflex Chronotropic and Inotropic Effects of Calcium Channel‐Blocking Agents in Conscious Dogs: Diltiazem, Verapamil, and Nifedipine Compared , 1983, Circulation research.

[3]  T. Begenisich,et al.  Adrenergic modulation of the delayed rectifier potassium channel in calf cardiac Purkinje fibers. , 1986, Biophysical journal.

[4]  Relationship Between an Arrhythmogenic Action of Lidocaine and Its Effects on Excitation Patterns in Acutely Ischemic Porcine Myocardium , 1986, Journal of cardiovascular pharmacology.

[5]  D. Wyse,et al.  Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans. , 1987, Journal of the American College of Cardiology.

[6]  Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias. , 1990, Journal of the American College of Cardiology.

[7]  M. Freysz,et al.  Profibrillatory Effects of Lidocaine in the Acutely Ischemic Porcine Heart , 1995, Journal of cardiovascular pharmacology.

[8]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[9]  W. Crumb,et al.  Description of a nonselective cation current in human atrium. , 1995, Circulation research.

[10]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[11]  J Weissenburger,et al.  Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. , 1995, Journal of the American College of Cardiology.

[12]  CharlesAntzelevitch,et al.  Sodium Channel Block With Mexiletine Is Effective in Reducing Dispersion of Repolarization and Preventing Torsade de Pointes in LQT2 and LQT3 Models of the Long-QT Syndrome , 1997 .

[13]  A. Moss,et al.  Gene‐Specific Therapy for Long QT Syndrome , 1997 .

[14]  A. George,et al.  Pharmacological targeting of long QT mutant sodium channels. , 1997, The Journal of clinical investigation.

[15]  G. Ndrepepa,et al.  Actions of lidocaine on reentrant ventricular rhythms in the subacute myocardial infarction period in dogs. , 1997, The American journal of physiology.

[16]  H. Stass,et al.  Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. , 1999, The Journal of antimicrobial chemotherapy.

[17]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[18]  Katerina Hnatkova,et al.  Sex differences in the rate dependence of the T wave descending limb. , 2003, Cardiovascular research.

[19]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[20]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[21]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[22]  Borje Darpo,et al.  ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs , 2005 .

[23]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[24]  F. Persson.  Mechanism of Action of the Antiarrhythmic Agent AZD7009 , 2007 .

[25]  Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. , 2007, European journal of pharmacology.

[26]  J. Ruskin,et al.  Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. , 2008, Cardiovascular research.

[27]  L. S. Fridericia.  Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken , 2009 .

[28]  Automatic Extraction of ECG Strips from Continuous 12‐lead Holter Recordings for QT Analysis at Prescheduled versus Optimized Time Points , 2009, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[29]  I. Cohen,et al.  Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome , 2012, Science Translational Medicine.

[30]  Thomas O'Hara,et al.  Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. , 2012, American journal of physiology. Heart and circulatory physiology.

[31]  Lin Wu,et al.  A Novel, Potent, and Selective Inhibitor of Cardiac Late Sodium Current Suppresses Experimental Arrhythmias , 2012, The Journal of Pharmacology and Experimental Therapeutics.

[32]  N. Stockbridge,et al.  Dealing with Global Safety Issues , 2013, Drug Safety.

[33]  Li Zhang,et al.  Inhibition of Late Sodium Current by Mexiletine: A Novel Pharmotherapeutical Approach in Timothy Syndrome , 2013, Circulation. Arrhythmia and electrophysiology.

[34]  D. Roden,et al.  Screening for Acute IKr Block Is Insufficient to Detect Torsades de Pointes Liability: Role of Late Sodium Current , 2014, Circulation.

[35]  J Vicente,et al.  Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science , 2014, Clinical pharmacology and therapeutics.

[36]  J Vicente,et al.  Differentiating Drug‐Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and Verapamil , 2014, Clinical pharmacology and therapeutics.

[37]  Gary Gintant,et al.  Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. , 2014, American heart journal.

[38]  Jonathan H Seltzer,et al.  Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. , 2015, American heart journal.

[39]  C Garnett,et al.  Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase , 2015, Clinical pharmacology and therapeutics.

[40]  Norman Stockbridge,et al.  Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil , 2015, Journal of the American Heart Association.

[41]  E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs — Questions and Answers (R3) Guidance for Industry , 2017 .